Lymphoscintigraphy & Sentinel Node Mapping

Sentinel lymph node mapping succeeds or fails on the physics of the injected tracer. Particle size governs how the radiopharmaceutical migrates and is retained, administered activity and radioactive decay govern how much signal survives to the operating room, and a well-tuned gamma camera plus a calibrated gamma probe turn that signal into an accurate map of lymphatic drainage.¹²

Lymphoscintigraphy is one of the most physics-dependent routine procedures in nuclear medicine. The clinical question — which node drains this tumor first? — is answered not by the drug's pharmacology alone but by colloid particle size, injection technique, tracer kinetics, collimator and energy-window choices, and the count statistics the surgeon relies on hours later. This guide connects those pieces so that a medical physicist, technologist, or radiation safety officer can build a defensible sentinel node program.¹²

Introduction

Lymphoscintigraphy is a nuclear medicine imaging procedure that traces the lymphatic drainage of a tumor to identify the sentinel lymph node (SLN) — the first node reached by lymph leaving the tumor. Because cancer cells spread along the same lymphatic channels, the sentinel node is the most likely first site of nodal metastasis. If it is tumor-free, the rest of the basin is usually spared a full lymph node dissection, sparing patients the morbidity of that surgery.¹²

The procedure is a partnership between the radiopharmaceutical and the imaging chain. A small activity of a Tc-99m-labeled tracer is injected around the tumor; the tracer migrates through lymphatic vessels and is trapped in the sentinel node; the gamma camera images that migration, and a handheld gamma probe localizes the node during surgery. The physics of each step — how fast and how far the tracer moves, how much signal remains after decay, and how the imaging system counts that signal — determines whether the map is accurate.¹²

This article walks through the radiopharmaceuticals and why particle size matters, the imaging and intraoperative protocol, the dosimetry to patients and staff, quality-control considerations, and the regulatory context. DRPS supports these programs as part of its PET/CT and nuclear medicine physics and medical physics consulting services across Florida, Maryland, Virginia, Washington DC, California, Nevada, Pennsylvania, New York, New Jersey, and Delaware.

Topic Explanation

What happens during a sentinel node study

A sentinel node study has three physical stages:

1. Injection. A small volume of Tc-99m-labeled tracer is placed near the tumor — intradermally over a melanoma, or peritumorally, subareolarly, or subdermally for breast cancer. The route and depth are chosen to feed the lymphatic channels that drain the tumor.¹²
2. Migration and trapping. The tracer enters lymphatic capillaries and travels to the first draining node, where it is retained — by phagocytosis for colloids, or by receptor binding for tilmanocept.¹⁷
3. Detection. A gamma camera produces dynamic and static planar images (often with SPECT/CT for anatomic localization), and in the operating room a gamma probe or portable gamma camera guides excision of the hot node.¹²

Because the sentinel node concept depends on identifying the first node reliably, every stage has to preserve the spatial and count information that tells the surgeon which node to remove. Related imaging-chain topics are covered in gamma camera collimator selection and SPECT/CT quality control.

Tc-99m: the workhorse radionuclide

Nearly all sentinel node agents are labeled with technetium-99m, whose properties make it nearly ideal for this task: a physical half-life of 6.0067 hours, a single dominant gamma emission at 140.5 keV with an abundance of about 89%, and no particle emission that would add dose without adding image information.⁵ The 140 keV photon is energetic enough to escape tissue and be collimated efficiently, yet low enough for a compact intraoperative probe to detect. The ~6-hour half-life is long enough to support both same-day and 2-day protocols but short enough that any residual activity in an excised specimen decays quickly.

Key Technical Principles

Particle size drives colloid migration

For colloidal tracers, the single most important physical parameter is particle size. Colloids are trapped in the node by macrophage phagocytosis, and the size distribution controls the trade-off that defines a good lymphoscintigraphy agent:

• Too small (well under ~50 nm): rapid clearance from the injection site and fast nodal transit, but a tendency to pass through the sentinel node into second-echelon nodes, blurring the "first node" answer.
• Too large (many hundreds of nm and up): strong retention but sluggish migration, so the tracer may not reach the node in a usable time window.
• Intermediate: the practical sweet spot for reliable sentinel-node visualization.¹¹⁰

Tc-99m tilmanocept (Lymphoseek) breaks this trade-off. It is not a colloid but a small (~7 nm) mannosyl–dextran molecule that binds the CD206 mannose receptor on nodal macrophages and dendritic cells. Because uptake is receptor-mediated rather than size-dependent, it clears the injection site rapidly while binding avidly in the sentinel node, and in comparative trials it identified sentinel nodes with high concordance to vital blue dye while removing fewer nodes on average than filtered sulfur colloid.⁵⁷⁸⁹

The vial content and activity are agent-specific: a Lymphoseek kit reconstitutes to about 92.5 MBq (2.5 mCi) of Tc-99m tilmanocept carrying 250 µg of tilmanocept, from which patient doses are drawn.⁵

Administered activity, decay, and the operating-room window

Sentinel node work uses small activities, but the tracer must still deliver enough counts to the node at the time of surgery, which may be many hours after injection. The EANM melanoma guideline uses roughly 15 MBq for same-day surgery up to 120 MBq for a 2-day protocol, in a total volume of about 0.4–1.0 mL, injected intradermally, with a target of at least 10 MBq available at the time of surgery.²

Whether that target is met is a decay problem. Activity remaining after time $t$ follows the exponential decay law:

$$A(t)=A_0{e}^{-\lambda t},\lambda =\frac{\ln 2}{T_{1/2}}=\frac{0.693}{6.0067\text{h}}=0.1154{\text{h}}^{-1}$$

Consider a dose calibrated at 92.5 MBq at 06:00 and injected at 12:00, so $t=6.0$ h:

$$A=92.5\times e^{-0.1154\times 6.0}=92.5\times e^{-0.692}=92.5\times 0.500=46.3\text{MBq}$$

After roughly one half-life, about half the activity remains — the intuition behind Tc-99m dosing. Now consider a 2-day melanoma protocol where surgery occurs 20 hours after a 120 MBq injection:

$$A=120\times e^{-0.1154\times 20}=120\times e^{-2.31}=120\times 0.0996=12.0\text{MBq}$$

That is just above the guideline's 10 MBq operating-room floor, which is exactly why 2-day protocols must start with a high injected activity: the tracer has to survive nearly three and a half half-lives and still exceed the count level the probe needs.²

Imaging chain and intraoperative detection

Planar and SPECT/CT images are acquired with a gamma camera fitted with a low-energy high-resolution (LEHR) collimator and a 20% energy window centered on the 140 keV photopeak — the same configuration used across general Tc-99m imaging.¹² Dynamic imaging early after injection captures lymphatic channels and distinguishes true sentinel nodes from downstream nodes; delayed static images and SPECT/CT localize the node against anatomy, which is especially valuable in the head and neck and pelvis.

In the operating room, a handheld gamma probe converts the residual activity into an audible count rate. The 10% rule governs how many nodes are taken: after the hottest node is removed and counted ex vivo, any additional node measuring at least 10% of that hottest node's count is also harvested. Removing only the single hottest node would miss a tumor-positive node in about 13% of positive basins, so the rule is a deliberate sensitivity safeguard grounded in count statistics.¹²

Clinical Impact

The physics choices above translate directly into clinical performance:

• Accuracy of staging. A correctly identified, tumor-free sentinel node lets a surgeon safely omit a complete nodal dissection. An agent that migrates too far or a protocol that lets activity decay below the probe's threshold can cause a sentinel node to be missed or a wrong node to be sampled.
• Fewer nodes, less morbidity. Receptor-targeted tilmanocept tends to concentrate signal in true sentinel nodes and removes fewer nodes on average than filtered sulfur colloid, which can reduce surgical morbidity while preserving detection.⁸⁹
• Patient comfort. Injection-site pain differs by agent and technique; small-volume, receptor-targeted injection is generally better tolerated than large-volume colloidal injection.⁹
• Workflow flexibility. The choice between same-day and 2-day protocols is a scheduling and decay decision. A 2-day protocol decouples imaging from surgery but demands higher injected activity to preserve the operating-room count level, as the decay calculation above shows.²

For programs adding SPECT/CT localization, the anatomic map is only as good as the underlying camera calibration — see SPECT/CT quality control and gamma camera uniformity QC.

Practical Optimization Tips

A defensible sentinel node program tends to share the same operational habits.

1. Match the agent and particle size to the clinical question

Choose the tracer deliberately. If rapid, clean injection-site clearance and fewer removed nodes matter, a receptor-targeted agent has advantages; if a colloid is used, understand its size distribution and filtration state, because those determine migration speed and second-echelon spillover.⁷¹⁰

2. Verify activity at injection, not just at calibration

Because the operating-room count level depends on decay, confirm the drawn activity in a calibrated dose calibrator immediately before injection and document the injection time. For 2-day protocols, work the decay backward from the planned surgery time to set the injected activity so that at least the guideline floor of usable activity remains.² See dose calibrator quality control.

3. Standardize injection technique

Route, depth, volume, and number of injections all affect drainage. Standardizing technique — and using dynamic imaging to confirm channels — reduces the chance of visualizing a non-sentinel node or failing to visualize the true one.¹²

4. Optimize the imaging configuration

Confirm the LEHR collimator, 140 keV photopeak, and 20% window before each study, and use a transmission source or SPECT/CT to place hot spots in anatomic context. A daily gamma-camera QC that verifies energy peaking and uniformity protects every subsequent map.¹

5. Calibrate and check the gamma probe

The intraoperative probe is a measuring instrument. Verify its energy response, sensitivity, and background before cases, and apply the 10% ex-vivo rule consistently so node selection is reproducible rather than operator-dependent.¹²

6. Manage the radioactive specimen sensibly

Excised sentinel nodes carry small residual activity. Label specimens, minimize direct handling time, and — where local procedures call for it — allow short-term decay before routine pathology handling. The measured hazard is very low, as the dosimetry section shows.¹³¹⁴

Common pitfalls to avoid

• Ignoring decay in a 2-day protocol. Injecting a same-day activity for next-day surgery can leave too few counts for reliable localization.
• Assuming all colloids behave alike. Filtered and unfiltered sulfur colloid, nanocolloid, and tilmanocept differ in migration and retention.
• Skipping dynamic imaging. Static images alone can mislabel a second-echelon node as sentinel.
• Treating the probe as pre-calibrated. An unchecked probe undermines the 10% rule and node selection.

Regulatory Considerations

Sentinel lymph node injection is a diagnostic imaging use of unsealed byproduct material, governed by 10 CFR Part 35 — specifically the imaging and localization provisions of 10 CFR 35.200 — and it does not require a written directive.¹⁵ Written directives under 10 CFR 35.40 apply to therapeutic administrations and specific radioiodine thresholds, not to diagnostic sentinel node localization. That distinction matters for program documentation: sentinel node studies follow the authorized user, dosimetry, survey, and record-keeping requirements for diagnostic use rather than the written-directive workflow used for therapies.¹⁵

Authorized users must meet the training and experience requirements for imaging and localization studies under Part 35, and the tracer must be prepared and administered under the facility's radioactive material license. Handling of the radioactive surgical specimen — including any decay-in-storage or survey steps — should be covered in the facility's procedures so pathology staff and the operating room have clear guidance.

Jurisdiction depends on the state. Byproduct material such as Tc-99m tracers is regulated by the NRC or by an Agreement State radiation-control program. Of the areas DRPS serves, Florida, Maryland, Virginia, California, Nevada, Pennsylvania, New York, and New Jersey are NRC Agreement States that license medical use under their own regulations, while Washington, DC and Delaware are regulated directly by the NRC. A facility must confirm which authority issues its license and which specific requirements apply. For the training pathway, see authorized user and medical physicist training and experience.

The federal dose framework — 10 CFR Part 20 occupational and public dose limits — sets the ceiling against which the very low staff doses from sentinel node work are compared. As the next section shows, those doses leave a wide margin.

Frequently Asked Questions (FAQs)

What is lymphoscintigraphy?

Lymphoscintigraphy is a nuclear medicine procedure that injects a small quantity of a Tc-99m-labeled radiotracer near a tumor and images its drainage through the lymphatic system to identify the sentinel lymph node — the first node that receives lymph from the tumor site. It guides sentinel lymph node biopsy in breast cancer, melanoma, and other cancers.

Which radiopharmaceuticals are used for sentinel node mapping?

In the United States the most common agents are filtered and unfiltered Tc-99m sulfur colloid and Tc-99m tilmanocept (Lymphoseek). In Europe, Tc-99m nanocolloidal human serum albumin is standard. Sulfur colloid and nanocolloid are trapped in the node by particle size, while tilmanocept binds a specific mannose receptor on nodal macrophages.

Why does particle size matter in lymphoscintigraphy?

For colloidal agents, particle size controls how quickly the tracer leaves the injection site and how strongly it is retained in the sentinel node. Very small particles migrate rapidly but may pass through to second-echelon nodes, while very large particles stay at the injection site. Tilmanocept sidesteps this trade-off by binding a receptor rather than relying on size-dependent trapping.

How much radioactivity does a patient receive, and what is the dose?

Administered activity is small — roughly 15 MBq for a same-day protocol up to about 120 MBq for a 2-day protocol. Published dosimetry for a common 18.5 MBq breast protocol gives an effective dose on the order of 0.46 mSv, with the injection site receiving the highest local dose and any fetal dose well below reporting thresholds.

Does sentinel node injection require a written directive?

No. Sentinel lymph node injection is a diagnostic imaging use of unsealed byproduct material under 10 CFR 35.200. Written directives under 10 CFR 35.40 apply to specific therapy administrations, not to diagnostic sentinel node localization. Authorized user, dosimetry, and radiation safety requirements still apply.

Is the surgically removed radioactive node a radiation hazard to staff?

No, at the activities used the hazard is negligible. Published studies report surgeon hand doses on the order of hundredths of a millisievert per operation and pathologist hand doses below detection limits. Reasonable practices — brief handling, standard specimen labeling, and short-term storage for decay when needed — keep occupational dose far below regulatory limits.

What is the "10% rule" in intraoperative counting?

After the hottest sentinel node is removed and counted ex vivo with the gamma probe, any additional node reading at least 10% of that hottest node's count is also considered a sentinel node and removed. This rule improves sensitivity: removing only the single hottest node would miss a tumor-positive node in a meaningful fraction of cases.

Key Takeaways

• Particle size is the master variable for colloids. It sets the balance between fast migration and reliable sentinel-node retention; tilmanocept avoids the trade-off with receptor-specific binding.⁷¹⁰
• Decay defines the operating-room window. Activity falls as $A_0{e}^{-\lambda t}$; a 2-day protocol must start high (up to ~120 MBq) to keep at least ~10 MBq usable at surgery.²
• Tc-99m is nearly ideal. A 6.0 h half-life, 140 keV photon, and ~89% abundance suit both camera imaging and intraoperative probe detection.⁵
• The 10% ex-vivo rule protects sensitivity. Removing only the hottest node would miss tumor-positive nodes in about 13% of positive basins.¹²
• Patient and staff doses are low. A common breast protocol gives ~0.46 mSv effective dose, and surgeon/pathologist hand doses are small fractions of occupational limits.¹¹¹³¹⁴
• It is a diagnostic use. Sentinel node injection falls under 10 CFR 35.200 and requires no written directive, but full diagnostic radiation-safety requirements apply.¹⁵

Conclusion

Lymphoscintigraphy looks simple — a small injection and a picture of where it goes — but its reliability rests on physics. The agent's particle size or binding mechanism determines whether the tracer marks the true first node; the injected activity and the exponential decay of Tc-99m determine whether the surgeon has enough signal hours later; and the collimator, energy window, and calibrated probe determine whether that signal becomes an accurate map. A program that treats these as deliberate, documented choices — rather than defaults inherited from another site — will localize sentinel nodes more consistently and defend its results under review.

The medical physicist's role is to keep those choices explicit: verify the tracer and its activity, confirm the imaging configuration, calibrate the probe, apply the 10% rule consistently, and document the low but real radiation-safety footprint of the radioactive specimen. Done well, sentinel node mapping delivers accurate staging with a small radiation dose and a light operational burden.

How DRPS Can Help

Diagnostic Radiation Physics Services helps nuclear medicine programs turn sentinel node mapping into a documented, defensible workflow. This can include gamma camera and SPECT/CT performance testing, dose calibrator and gamma probe verification support, protocol review for same-day versus 2-day activity selection, radioactive-specimen handling procedures, and radiation safety program support aligned with NRC and Agreement State requirements — delivered through our PET/CT and nuclear medicine physics and medical physics consulting services.

DRPS supports facilities across our service locations, including Florida, Maryland, Virginia, Washington DC, California, Nevada, New York, Pennsylvania, New Jersey, and Delaware. To discuss a sentinel node program, contact our team.

Related Resources

• Gamma camera collimator selection
• SPECT/CT quality control
• Gamma camera uniformity QC
• Dose calibrator quality control
• Tc-99m MDP bone scintigraphy
• Authorized user and medical physicist training and experience
• PET/CT and nuclear medicine physics services
• Medical physicist consulting

References

1. Giammarile F, Alazraki N, Aarsvold JN, et al. The EANM and SNMMI practice guideline for lymphoscintigraphy and sentinel node localization in breast cancer. Eur J Nucl Med Mol Imaging. 2013;40(12):1932-1947. doi:10.1007/s00259-013-2544-2. PubMed
2. Bluemel C, Herrmann K, Giammarile F, et al. EANM practice guidelines for lymphoscintigraphy and sentinel lymph node biopsy in melanoma. Eur J Nucl Med Mol Imaging. 2015;42(11):1750-1766. doi:10.1007/s00259-015-3135-1. PubMed
3. Giammarile F, Bozkurt MF, Cibula D, et al. The EANM clinical and technical guidelines for lymphoscintigraphy and sentinel node localization in gynaecological cancers. Eur J Nucl Med Mol Imaging. 2014;41(7):1463-1477. doi:10.1007/s00259-014-2732-8. PubMed
4. Giammarile F, Schilling C, Gnanasegaran G, et al. The EANM practical guidelines for sentinel lymph node localisation in oral cavity squamous cell carcinoma. Eur J Nucl Med Mol Imaging. 2019;46(3):623-637. doi:10.1007/s00259-018-4235-5. PubMed
5. U.S. Food and Drug Administration. Lymphoseek (technetium Tc 99m tilmanocept) injection — Prescribing Information. 2021. accessdata.fda.gov
6. International Commission on Radiological Protection. ICRP Publication 128: Radiation Dose to Patients from Radiopharmaceuticals — A Compendium of Current Information Related to Frequently Used Substances. Ann ICRP. 2015;44(2 Suppl). icrp.org
7. Leong SP. Detection of melanoma, breast cancer and head and neck squamous cell cancer sentinel lymph nodes by Tc-99m Tilmanocept (Lymphoseek). Clin Exp Metastasis. 2022;39(1):39-50. doi:10.1007/s10585-021-10137-4. PubMed
8. Wallace AM, Han LK, Povoski SP, et al. Comparative evaluation of [99mTc]tilmanocept for sentinel lymph node mapping in breast cancer patients: results of two phase 3 trials. Ann Surg Oncol. 2013;20(8):2590-2599. doi:10.1245/s10434-013-2887-8. PubMed
9. Baker JL, Pu M, Tokin CA, et al. Comparison of [99mTc]tilmanocept and filtered [99mTc]sulfur colloid for identification of sentinel lymph nodes in breast cancer patients. Ann Surg Oncol. 2015;22(1):40-45. doi:10.1245/s10434-014-3892-2. PubMed
10. Tsopelas C. Particle size analysis of 99mTc-labeled and unlabeled antimony trisulfide and rhenium sulfide colloids intended for lymphoscintigraphic application. J Nucl Med. 2001;42(3):460-466. PubMed
11. Pandit-Taskar N, Dauer LT, Montgomery L, et al. Organ and fetal absorbed dose estimates from 99mTc-sulfur colloid lymphoscintigraphy and sentinel node localization in breast cancer patients. J Nucl Med. 2006;47(7):1202-1208. PubMed
12. McMasters KM, Reintgen DS, Ross MI, et al. Sentinel lymph node biopsy for melanoma: how many radioactive nodes should be removed? Ann Surg Oncol. 2001;8(3):192-197. doi:10.1007/s10434-001-0192-4. PubMed
13. Peștean C, Larg MI, Bărbuș E, et al. Quantification of radiation exposure of non-dominant index for the surgeon performing sentinel lymph-node removal procedure. Curr Radiopharm. 2018;11(1):64-68. doi:10.2174/1874471011666180206165744. PubMed
14. Klausen TL, Chakera AH, Friis E, et al. Radiation doses to staff involved in sentinel node operations for breast cancer. Clin Physiol Funct Imaging. 2005;25(4):196-202. doi:10.1111/j.1475-097X.2005.00611.x. PubMed
15. U.S. Nuclear Regulatory Commission. 10 CFR Part 35: Medical Use of Byproduct Material. ecfr.gov